Genzyme and Viacell have signed a deal to jointly develop a treatment for juvenile diabetes, with Genzyme paying the costs of development until the therapy is ready for human clinical trials. Viacell's research involves the use of pancreatic tissue from cadavers to produce islet cells that can be introduced into a patient's liver to begin producing insulin.

Related Summaries